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Abstract
Objective: Metastasis is the most common cause of death of prostate cancer patients. Identification of specific metastasis
biomarkers and novel therapeutic targets is considered essential for improved prognosis and management of the disease.
MicroRNAs (miRNAs) form a class of non-coding small RNA molecules considered to be key regulators of gene expression.
Their dysregulation has been shown to play a role in cancer onset, progression and metastasis, and miRNAs represent a
promising new class of cancer biomarkers. The objective of this study was to identify down- and up-regulated miRNAs in
prostate cancer that could provide potential biomarkers and/or therapeutic targets for prostate cancer metastasis.
Methods: Next generation sequencing technology was applied to identify differentially expressed miRNAs in a
transplantable metastatic versus a non-metastatic prostate cancer xenograft line, both derived from one patient’s primary
cancer. The xenografts were developed via subrenal capsule grafting of cancer tissue into NOD/SCID mice, a methodology
that tends to preserve properties of the original cancers (e.g., tumor heterogeneity, genetic profiles).
Results: Differentially expressed known miRNAs, isomiRs and 36 novel miRNAs were identified. A number of these miRNAs
(21/104) have previously been reported to show similar down- or up-regulation in prostate cancers relative to normal
prostate tissue, and some of them (e.g., miR-16, miR-34a, miR-126*, miR-145, miR-205) have been linked to prostate cancer
metastasis, supporting the validity of the analytical approach.
Conclusions: The use of metastatic and non-metastatic prostate cancer subrenal capsule xenografts derived from one
patient’s cancer makes it likely that the differentially expressed miRNAs identified in this study include potential biomarkers
and/or therapeutic targets for human prostate cancer metastasis.
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Introduction
Prostatecanceristhemostcommoncancerinmenandthesecond
leading cause of cancer deaths in the United States [1]. While
considerable advances have been made in the treatment of localized,
organ-confined tumors, prostate cancer is currently incurable once it
has progressed to metastasis, and most deaths from this disease are
due to metastases that are highly resistant to conventional therapies.
Currently, prostate-specific antigen (PSA) is a major serum
biomarker used for the detection and monitoring of prostate cancer
progression.However,the prognosticvalueofincreasedPSAlevelsis
limited, since advanced prostate cancer can be associated with very
low or normal PSA values. There is therefore an urgent need for
new, more specific biomarkers which can be used to predict cancer
progression on their own or in cooperation with a current biomarker
such as PSA [2]. Furthermore, novel therapeutic targets associated
with prostate cancer metastasis are urgently needed.
MicroRNAs (miRNAs) are small non-coding RNAs (17 to 27
nucleotides) that negatively regulate the expression of target genesby
binding to 39 untranslated regions (UTRs) of mRNAs and inhibiting
translation or promoting mRNA degradation [3]. Recent studies
have shown dysregulation of miRNAs in human tumors indicating a
role for such molecules in cancer pathogenesis, including cancer
onset, progression and metastasis [4,5]. Thus far, only a small
number of studies have investigated miRNA expression in prostate
cancer, and only a few have dealt with metastasis of this disease.
Differences in the expression profiles of miRNAs so far identified
may have prognostic value for the various aspects of the disease and
a better understanding of the role of miRNAs in the development
and progression of prostate cancer is needed [6]. Further research
may also lead to identification of new miRNAs that are specifically
related to prostate cancer progression and metastasis. Such
metastasis-associated miRNAs may serve as metastatic biomarkers
and/or new targets for therapy of metastatic disease.
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prostate cancer metastasis have been impeded by a lack of optimal
experimental models. While xenograft models based on estab-
lished cancer cell lines representing different stages of cancer
progression can be useful for identifying mechanisms underlying
metastasis, they do not adequately mimic clinical disease [7].
Efforts have therefore focused on use of patients’ prostate cancer
tissues. However, the typical heterogeneity of such tissues,
consisting of both non-metastatic and potentially metastatic
subpopulations, makes it difficult to identify factors such as genes
that underlie the development of metastasis [8]. Moreover, it is
difficult to obtain metastatic prostate cancer tissues from patients
for experimental purposes, since they are not routinely or feasibly
biopsied or resected from patients, and rapid autopsy programs
are extremely expensive and difficult to manage. To overcome the
above hurdles, we developed next generation patient-derived
prostate cancer xenograft models, that more closely resemble the
clinical situation, by using subrenal capsule grafting of patients’
cancer tissue into immuno-deficient mice. This methodology
favors retention of the properties of the original cancers [9–11].
Furthermore, it has been possible to establish transplantable,
metastatic and non-metastatic prostate cancer sublines from
heterogeneous xenografts [12,13]. Use of metastatic and non-
metastatic xenografts has already been effective in the identifica-
tion of prostate cancer metastasis-associated genes [13].
Illumina’s massively parallel DNA sequencing by synthesis
technology is a widely-adopted next-generation sequencing
platform. It supports parallel sequencing using a proprietary
reversible terminator-based method that enables detection of
single bases as they are incorporated into growing DNA strands. A
fluorescently-labeled terminator is imaged as each dNTP is added
and then cleaved to allow incorporation of the next base. Since all
four reversible terminator-bound dNTPs are present during each
sequencing cycle, natural competition minimizes incorporation
bias, leading to true base-by-base sequencing [14].
In the present study, Illumina next generation sequencing
technology was utilized to compare the miRNA profiles of a
transplantable metastatic versus a non-metastatic prostate cancer
xenograft line, both derived via subrenal capsule grafting [10–12]
from one patient’s primary cancer tissue. Differentially expressed
known and novel miRNAs were found that may have specific roles
in the metastasis of prostate cancer.
Materials and Methods
Patient-derived prostate cancer xenograft models
NOD/SCID mice used for xenografting were bred and
maintained at the British Columbia Cancer Research Centre
Animal Facility (Vancouver, Canada). All experimental protocols
were approved by the University of British Columbia Animal Care
Committee (A10-0100). A prostate cancer biopsy specimen was
obtained at the BC Cancer Agency with the patient’s written
informed consent. Ethical approval was provided by the University
of British Columbia - British Columbia Cancer Agency Research
Ethics Board (UBC BCCA REB #H04-60131).
The establishment of transplantable prostate cancer tissue
xenograft lines via subrenal capsule grafting has been described
previously [9]. In the present study, a recently prepared metastatic
prostate cancer xenograft line, LTL-313H [15], and a non-
metastatic counterpart, LTL-313B (unpublished), were used that
had been derived from different loci of one patient’s prostate
cancer biopsy sample (www.livingtumorlab.com). Both lines were
PSA- and AR-positive as shown via immunohistochemistry ([15];
unpublished data). They were routinely maintained under renal
capsules of male NOD/SCID mice supplemented with testoster-
one, as previously described [9]. The LTL-313H xenografts
showed invasion of the mouse host kidney and cancer cells were
detected in the lungs of the hosts after 3 months of grafting. In
contrast, the LTL-313B xenografts showed no obvious invasion of
the mouse kidney and did not show any distant metastases (data
not shown).
Small RNA library construction and cDNA sequencing
LTL-313H and LTL-313B xenograft tissues were collected and
RNA was extracted using TRIzol (Invitrogen, Mississauga, ON,
Canada) according to the manufacturer’s instructions. The RNA
was submitted to the Genome Sciences Centre at the British
Columbia Cancer Agency (www.bcgsc.bc.ca) for small-RNA
cDNA library construction and sequencing as previously described
[16] with minor modifications. Each library had a specific index
sequence in its 59 adaptor, i.e. ‘‘ACATCGA’’ for the LTL-313H
library and ‘‘CGTGATA’’ for the LTL-313B library; both
libraries were mixed and the sequencing was run in one flow
cell in the Illumina’s platform.
Small RNA mapping and differential expression detection
The 59 indexed cDNA sequences were used to distinguish the
origin of the RNAs. 39 Adaptor sequences were removed from all
reads and those remaining tags that were 16 to 27 nucleotides in
length and expressed at a tag count of 2 or more in each library
were used for further analysis. The trimmed sequences were
mapped to miRBase 15 human stem-loop sequences (http://www.
mirbase.org/) using the Novoalign (www.novocraft.com) program
allowing up to 3 mismatches. Those that matched an miRBase
sequence were then grouped as: 1) known mature miRNA and
miRNA*, 2) putative miRNA*, not previously reported in the
miRBase, 3) loop sequences and 4) sequences which matched the
loop-sequence but did not have known mature sequences. The
sequences matching known miRNAs were further clustered, based
on their starting positions, and counted. The most abundant
variation/starting position tags were used for comparison between
libraries. Tag counts were normalized to the total counts of those
sequences which matched the miRBase 15 stem-loop sequences
and the two libraries were compared for differential expression of
the sequences using the Fisher’s exact test with Bonferroni’s
correction. Sequences were deemed significantly differentially
expressed by the two libraries if the p-value was ,0.001 and there
was at least a 2–fold change in the sequences’ normalized counts.
Novel miRNA identification
The sequences that did not match known miRNA stem-loop
sequences were filtered out with known transcripts sequences
downloaded from UCSC [17]. To identify novel miRNA
candidates amongst the remaining unmatched sequences, the
miRanalyzer program [18] was used (http://web.bioinformatics.
cicbiogune.es/microRNA/miRanalyser.php). The output candi-
dates were checked one by one for homologies to known non-
coding RNA, and non-homologous sequences were taken as novel
miRNA candidates.
miRNA target prediction and pathway analysis
The target genes for each differentially expressed miRNA were
predicted using MicroCosm version 5 [19,20] with a threshold of
p=0.001. As some of the genes were potentially regulated by both
up-regulated and down-regulated miRNAs, we focused for further
analysis on the genes that were potentially regulated only by up-
regulated or down-regulated miRNAs. Identification of KEGG
miRNAs Associated with Metastatic Prostate Cancer
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using DAVID 6.7 (Database for Annotation, Visualization and
Integrated Discovery, http://david.abcc.ncifcrf.gov/). In addition,
we compared the target gene lists with gene expression data by
microarray assay using the same xenograft tissues to identify those
putative targets that might be regulated at the mRNA level.
Microarray gene expression analysis
The RNA that was used for the miRNA sequencing library was
also used for mRNA-based gene expression analysis using the
Agilent’s Human GE 44K platform at the Vancouver Prostate
Centre Microarray Facility (www.mafpc.ca). All data are MIAME
compliant and the raw data have been deposited in GEO
(accession number GSE28029). The expression signal was
transformed to z-score and calculated z-ratio and the mRNAs
with more than 1.96 of z-ratio were dealt up-regulated and less
than 21.96 as down-regulated [21]. The data were also filtered by
Flag.
Cell culturing
The 22Rv1 prostate cancer cell line was cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS) at 37uC
in a humidified atmosphere containing 5% CO2.
miRNA precursor transfection
The precursor sequence of mir-486, shown in the miRBase, and
a non-silencing negative control were subcloned into the
pcDNA6.2-GW/EmGFP miR plasmid (Invitrogen). 22Rv1 cells
were seeded in 12 well-plates at a density of 1.0610
5 cells per well,
24 hours in advance of transfection. Transfection was carried out
using Lipofectamine 2000 (Invitrogen), following the manufactur-
er’s instructions. The transfection efficiency was validated by GFP
signal monitoring using an inverted fluorescence microscope
system (Zeiss). To confirm increased levels of mature target
miRNA, a portion of the transfected cells was used for validation
by quantitative (qPCR). To this end, total RNA was extracted
using a miRNeasy mini kit (Qiagen) and the quantity of RNA
determined by nanodrop spectrophotometry (Thermo Scientific).
Portions (25 ng) of each of the total RNA preparations were
reverse-transcribed to cDNA using a Universal cDNA Synthesis
Kit (Exiqon) following the manufacturer’s instructions. The cDNA
was diluted and mixed with microRNA LNA PCR primers and
SYBR Green master mix (Exiqon). qPCR was carried out using an
ABIPrism 7900HT (Applied Biosystems) following the manufac-
turer’s instructions. The DDCT was used for calculating the fold
changes relative to the control and U6 was used as an endogenous
control.
MTT assay
The transfected cells were seeded in 96-well plates at a density
of 1610
4 cells/well. MTT solution (20 ml of 5 mg/ml) was added
to the cultures (200 ml volumes) for a 4 hr incubation at 37uC.
Following removal of the culture medium, the remaining crystals
were dissolved in DMSO and absorbance at 570 nm was
measured.
Migration/invasion assay
BioCoat Matrigel invasion chambers (BD Biosciences) were
used to measure tissue invasiveness of cells. In the upper chambers,
1610
5 cells/well were plated in 0.50 ml of serum-free medium. In
the lower chambers, 0.75 ml of medium/10% FBS was delivered.
The chambers were incubated for 30 hr at 37uC in a humidified
atmosphere with 5% CO2. The cells that remained in the upper
chamber were removed and the transmigrated cells fixed in
methanol and stained with crystal violet and stained cells were
counted by microscopic analysis. Tumor cell invasion was
expressed as the percentage of cells that had passed through the
Matrigel-coated membranes relative to the number of cells that
had passed through the uncoated membranes (invasion index). All
assays were performed in triplicate.
Results
miRNA sequencing and annotation
Small RNAs were isolated from metastatic LTL-313H and non-
metastatic LTL-313B prostate cancer tissue xenografts and
processed to allow deep sequencing using the Illumina’s platform.
The reads with adaptor index sequences ‘‘ACATCGA’’ and
‘‘CGTGATA’’ were given LTL-313H origin and LTL-313B
origin, respectively. More than 10 million total reads were
obtained for each of the libraries. These reads were compared
with the sequence data in the miRBase 15 microRNA Sequence
Database. For the metastatic and non-metastatic prostate cancer
tissue libraries, 3,445,642 and 2,272,677 tags, respectively, were
fully mapped to human miRNA stem-loop sequences present in
the miRBase database (Table 1). The completely matched reads
were annotated, according to their position in the stem-loop
structure. A shift of up to 2 bases in the starting and ending
positions was allowed for sequences to be annotated as isomers of
known mature miRNAs (isomiRs). The total numbers of known
miRNAs plus miRNA*s in the metastatic and non-metastatic
libraries were 447 and 509, respectively (Table 1). The most highly
expressed miRNA (and isomiR) was the miR-148a with total
counts of 270,801 and 763,877 reads per metastatic and non-
metastatic libraries, respectively. When the isomiRs were grouped
using the same starting position, the miR-148a remained the most
abundant miRNA in the non-metastatic library with a total count
of 846,468, whereas in the metastatic library miR-21 was most
abundant with a total count of 310,102.
miRNA and miRNA* expressions
In the miRBase, miRNAs derived from a precursor are
designated miRNA, the predominantly expressed arm, and
miRNA* the less-expressed, opposite arm. If both arms are
similarly expressed, they are referred to as 5p and 3p arms. The
expression of known miRNAs in the prostate cancer xenografts
was in general higher than that of miRNA*s. In a number of cases,
miRNA*s (as identified by miRBase) were more expressed than
the corresponding miRNAs (Table 2). Thus miR-144* was
substantially more expressed than miR-144 in both metastatic
and non-metastatic libraries; similarly miR-126* was more
expressed than miR-126, but only in the non-metastatic library.
Differences were also found in the expression patterns of 3p and
5p arm miRNAs (Table 2). The 3p arms of miR-28 and miR-339
showed higher expressions than the corresponding 5p arms in the
metastatic line, whereas they showed lower expressions than the
corresponding 5p arms in the non-metastatic line. In the
metastatic line, the miR-542 showed up-regulation of the 3p
arm but down-regulation of the 5p arm. Fragments that were
counterparts of known mature miRNAs, but that had not
previously been reported to the miRBase database, were
designated ‘‘putative novel miRNA*’’ species (Table 3). A total
of 32 of such putative miRNA*s was observed showing at least two
reads in one of the two libraries. Some of these miRNA*s also
showed higher expression than their corresponding miRNAs, e.g.,
miR-1277* and miR-1307*.
miRNAs Associated with Metastatic Prostate Cancer
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One advantage of utilizing a sequencing approach for miRNA
profiling is the opportunity to identify novel miRNAs or
miRNA*s. To this end, we used an miRanalyzer, a microRNA
detection and analysis tool [18], in combination with homology
searches to identify known transcripts, including non-coding
RNAs (e.g., rRNA, tRNA, etc.). Using miPred software to
distinguish real pre-miRNAs from other hairpin sequences with
similar stem-loops [22], we identified 36 novel miRNA candidates.
Their sequences, chromosome locations and number of reads in
the metastatic and non-metastatic libraries are presented in Table 4
and Table S1. Comparative analysis of the two libraries showed
significant differential expression of some of these novel miRNAs,
including down-regulated miR-5680-3p and miR-5681a-3p.
Potential metastasis-associated miRNAs
Comparative analysis of the metastatic and non-metastatic
xenograft miRNA libraries revealed a total of 104 differentially
expressed miRNAs or miRNA*s with 55 down-regulated and 49
up-regulated in the metastatic line (Table 5,6,7). Of the down-
regulated miRNAs, 24 miRNAs showed a .5-fold decrease,
including four miRNAs, i.e. miR-205, miR-503, miR-708 and
miR-2115*, which were undetectable in the metastatic line. Two
miRNAs, i.e. miR-24-2* and miR-101*, showed increased
expression in a one-base-shift form. A one-base-shift form of
miR-203 showed some increased expression in the metastatic line
relative to reference miR-203, whereas in the non-metastatic line it
showed a lower expression. Of the up-regulated miRNAs, 23
miRNAs showed a .5-fold change in normalized counts. One-
base-shift forms of miR-9*, miR-148b* and miR-1246 showed
higher expression than the reference forms in both metastatic and
non-metastatic lines.
Some of the differentially expressed miRNAs have previously
been associated with prostate cancer, prostate cancer metastasis or
metastasis of other types of cancer (Table 5,6,7). Of the down-
regulated miRNAs a number have been reported to be down-
regulated in prostate cancer relative to benign prostate tissues, i.e.
miR-16 [23–25], miR-24 [26–28], miR-29a [26], miR-145
[23,24,27,29,30], and miR-205 [24,31,32]. The down-regulation
of miR-16 [25], miR-34a [33], miR-126* [34], miR-145 [35] and
miR-205 [36] correlated with the development of prostate cancer
metastasis. Of the up-regulated miRNAs (in the metastatic library),
miR-210 has been reported to be up-regulated in prostate
carcinomas relative to BPH samples [23] and miR-301 has been
linked to prostate cancer metastasis [37]. In some cases, miRNAs
that were found to be up-regulated in the present study have been
reported to be either up-regulated in prostate carcinomas
compared to normal prostate tissue [38–40], or down-regulated
[23,24,27–29]. Furthermore, some of the differentially expressed
miRNAs have been reported to play a role in the metastasis of
other types of cancer, for example, the up-regulated miRNAs, let-
7i, miR-9, miR-30a, miR-125b, miR-142-5p, miR-151-3p, miR-
450a and the down-regulated miRNAs, miR-24, mir-145, miR-
146b-5p, miR-185, miR-186, miR-203 and miR-335.
Putative target genes for differentially expressed miRNAs
As a first step in the identification of miRNAs with potential
significance in the metastatic process, we identified putative target
genes for each of the differentially expressed miRNAs using
Microcosm analysis, a target prediction program with a specific
algorithm and coverage of miRNA, including varieties in star arms;
a threshold p-value=0.001 was maintained to get more reliable
target identification (Microcosm) [41]. Putative target genes were
Table 1. Small-RNA library sequencing summary.
Metastatic library Non-metastatic library
index tag sequence ACATCGA CGTGATA
total cDNA reads 10,525,988 11,644,175
reads mapped to miRNA miRBase stem-loop sequences 2,272,677 3,445,642
unique sequences 1,875,353 2,941,722
most abundant miRNA miR-148a (270,801) miR-148a (763,877)
most abundant miRNA grouped at starting position, total miR-21 (310,102) miR-148a (846,468)
total known miRNA plus miRNA* 447 509
doi:10.1371/journal.pone.0024950.t001
Table 2. Levels
a of miRNA and miRNA* showing
dysregulation in (i) miRNA:miRNA* ratios in metastatic and
non-metastatic xenografts and (ii) the levels of miRNA or
miRNA* in the two xenograft lines.
Expression level
miRNA metastatic non-metastatic fold change
miR-7 72.35 22.5 3.22
miR-7-1* 2.76 24.54 28.88
miR-126 26005.24 1799.7 14.45
miR-126* 1099.03 3798.06 23.46
miR-144 915.16 134.98 6.78
miR-144* 5429.24 418.37 12.98
miR-335 22.58 54.63 22.42
miR-335* 65.9 91.74 1.39
miR-374a 1638.17 674.3 2.43
miR-374a* 954.79 825.93 1.16
miR-28-3p 317.5 188.15 1.69
miR-28-5p 184.78 1264.17 26.84
miR-339-3p 65.43 102.55 21.57
miR-339-5p 35.94 189.03 25.26
miR-542-3p 100 26.88 3.72
miR-542-5p 0.92 12.27 213.31
aTag counts were normalized to the total counts of sequences that matched the
miRBase 15 stem-loop sequences and are expressed as number per 1,000,000
tags.
doi:10.1371/journal.pone.0024950.t002
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of 49 up-regulated miRNAs (Table S2); they were annotated using
the DAVID program. The putative target genes of the down-
regulated miRNAs were associated with a variety of KEGG
pathways including ‘‘Fc gamma R-mediated phagocytosis’’ and
‘‘ECM-receptorinteraction(TableS3).Forthe putativetargetgenes
of the up-regulated miRNAs, pathways such as ‘‘Pathways in
cancer’’, ‘‘Focal adhesion’’ and ‘‘Purine metabolism’’ were noted.
Comparison of putative miRNA target genes with
genes differentially expressed in the metastatic and
non-metastatic xenograft lines
Although miRNAs are thought to alter protein levels, they have
in some cases been shown to also affect mRNA levels [3]. In view
of this, the two xenograft lines were examined for differential
mRNA expression. As shown in the Table S4, 622 mRNAs were
down-regulated and 348 mRNAs were up-regulated in the
metastatic line. Some of the genes identified by differential mRNA
expression were potentially targeted by both up- and down-
regulated miRNAs. In view of this, further analysis was restricted
to genes that were potentially targeted by either up-regulated or
down-regulated miRNAs. The group that showed up-regulated
mRNAs associated with only down-regulated miRNAs consisted of
85 mRNAs; the group that showed down-regulated mRNAs
associated with only up-regulated miRNAs consisted of 58
mRNAs. Among the mRNAs up-regulated in the metastatic line,
some have been reported to have a role in tissue invasion and/or
metastasis of a variety of cancer cells, including mRNA expressed
by FSCN1 [42], VEGFA [43] FGFR1 [44], ADAMTS1 [45], CCL2
Table 3. Putative miRNA*s, i.e. fragments complementary to known miRNAs but not reported in the miRBase.
Expression levels
putative miRNA* sequence
matched to
miRNA stem-loop
starting
position putative miRNA* miRNA
metastatic non-metastatic metastatic non-metastatic
CTGTACAACCTTCTAGCTTTCC hsa-let-7c{ 56 4.15 1.17 2039.08 1584.38
TCAATAAATGTCTGTTGAAT hsa-mir-95 15 0 0.88 44.70 973.18
TATACAACTTACTACTTTCC hsa-mir-98 81 0 0.58 105.99 79.47
CGGGGCCGTAGCACTGTCTGA hsa-mir-128-1 15 0.92 0 42.39 5.26
ATGTAGGGATGGAAGCCATGA hsa-mir-135a-2 61 1.38 1.75 379.25 588.99
TGGAAACATTTCTGCACAAACT hsa-mir-147b 12 0 1.17 1.38 0.29
GTCATTTTTGTGATGTTGCAG hsa-mir-153-2 14 12.44 1.46 219.34 554.81
AGTGGTTCTTAACAGTTCAACA hsa-mir-203 27 0 6.14 116.12 296.54
AGCCCCTGCCCACCGCACACTG hsa-mir-210 28 1.38 1.17 13967.09 302.97
GCTCTGACGAGGTTGCACTACT hsa-mir-301b 10 1.38 0.88 4.15 3.21
GTTCCTGCTGAACTGAGCCAGT hsa-mir-3074 12 0 0.58 0.46 0.00
AGGGACTTTTGGGGGCAGATGTG hsa-mir-365-1 16 1.38 1.17 16.59 22.50
GCGACGAGCCCCTCGCACAAACC hsa-mir-375 5 0 0.88 6414.45 11574.16
TGTGTTGCATGTGTGTATATGT hsa-mir-466 14 0.92 0 0 0
CAAAAGCAATCGCGGTTTTTGC hsa-mir-548e 15 0 3.80 0.46 0
CAAAAACTGCAATTACTTTTGC hsa-mir-548h-3 65 0 0.58 0 0
TTTGGTGCATATTTACTTTAGG hsa-mir-559 57 2.76 0.58 0 0
ATCAAGGATCTTAAACTTTGCC hsa-mir-561 26 3.23 1.46 0 0.88
TCGCGGTTTGTGCCAGATGAC hsa-mir-579 25 0.92 0 0.46 2.34
ACAACCCTAGGAGAGGGTGCCATT hsa-mir-652 20 0 1.17 11.06 16.65
GGACCTTCCCTGAACCAAGGA hsa-mir-659 23 2.76 1.17 0 0
ACCTCCTGTGTGCATGGATT hsa-mir-660 52 0 1.17 32.26 68.37
CGGCCCCACGCACCAGGGTAAG hsa-mir-874 10 0.92 0 3.23 2.05
CGGGAACGTCGAGACTGGAGC hsa-mir-1247 77 0.92 0.58 0 0.29
CTATCTTCTTTGCTCATCCTTG hsa-mir-1255a 69 0 1.17 2.76 1.75
AGTTGGCATGGCTCAGTCCAAGT hsa-mir-1269 25 0 5.55 9.22 7.89
TATATATATATATGTACGTATG hsa-mir-1277 11 16.59 46.45 0 2.05
ATCTCACTTTGTTGCCCAGG hsa-mir-1285-1 13 0.92 0 0 2.05
CTCTAGCCACAGATGCAGTGAT hsa-mir-1287 55 0 2.05 0.92 7.89
GAGTGGGGCTTCGACCCTAACC hsa-mir-1296 59 0 0.58 10.60 12.27
CCACCTCCCCTGCAAACGTC hsa-mir-1306 15 1.38 1.75 0 0.58
TCGACCGGACCTCGACCGGCTCG hsa-mir-1307 41 82.48 126.50 11.98 26.59
{putative let-7c* sequence is not identical to the let-7c* in the miRBase but shows complementarity to let-7c.
doi:10.1371/journal.pone.0024950.t003
miRNAs Associated with Metastatic Prostate Cancer
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the metastatic line, including mRNAs expressed by the CTGF [48]
and SERPINB5 [49] genes, have been found to be down-regulated
in various metastatic cancers, attesting to the reliability of our
analyses (Table S5).
Increased levels of mature miR-486 in transfected cells
At 24 hours following transfection of 22Rv1 cells with
pcDNA6.2-GW/EmGFP-mir486 or pcDNA6.2-GW/EmGFP-
control sequence, more than 90% of the cells were found to be
GFP positive. The mir-486 precursor had been properly processed
to the mature miR-486 form as indicated by qPCR. Relative to the
control, the expression levels of both miR-486-5p and -3p arms
were 11.6 fold higher, indicating that the majority of the cells
expressed elevated miR-486 levels.
Invasiveness of miR-486-transfected 22Rv1 cells
The proliferation rate of miR-486-transfected and control
sequence-transfected cells was similar as indicated by the MTT
assay (Fig. 1A). However, the miR-486-transfected cells showed an
Table 4. Novel miRNA candidates.
reads in
ID Sequence chromosomal location metastatic non-metastatic
hsa-miR-5680-3p GAGAAATGCTGGACTAATCTGC 8q22.3 28 318
hsa-miR-5681a-3p AGAAAGGGTGGCAATACCTCTT 8q21.11 4 66
hsa-miR-5682-3p GTAGCACCTTGCAGGATAAGGT 3q13.33 2 29
hsa-miR-548aw-5p GTGCAAAAGTCATCACGGTT 9q34.13 26
hsa-miR-5683-5p TACAGATGCAGATTCTCTGACTTC 6p25.1 25 22
hsa-miR-5684-5p AACTCTAGCCTGAGCAACAG 19p13.13 2 2
hsa-miR-548ax-5p AGAAGTAATTGCGGTTTTGCCA Xp22.2 12
hsa-mir-5685-5p ACAGCCCAGCAGTTATCACGGG 6p12.1 9
hsa-miR-5692c-3p AATAATATCACAGTAGGTGTAC 5q31.1 8
7q21.3
hsa-miR-5686-5p TATCGTATCGTATTGTATTGT 10q24.1 8
hsa-miR-5687-3p TTAGAACGTTTTAGGGTCAAAT 5q11.2 6
hsa-miR-5688-3p TAACAAACACCTGTAAAACAGC 3p12.1 5
hsa-miR-5681b-5p AGGTATTGCCACCCTTTCTAGT 8q21.11 4
hsa-miR-548at-5p AAAAGTTATTGCGGTTTTGGC 17q21.31 4
hsa-miR-5689-5p AGCATACACCTGTAGTCCTAGA 6p24.3 4
hsa-miR-5690-5p TCAGCTACTACCTCTATTAGG 6p21.31 3
hsa-miR-5691-5p TTGCTCTGAGCTCCGAGAAAGC 11p15.4 3
hsa-miR-5692a-5p CAAATAATACCACAGTGGGTGT 7q21.3 3
8p23.1
hsa-miR-4666b-5p TTGCATGTCAGATTGTAATTCCC Xp21.2 3
hsa-miR-5693-3p GCAGTGGCTCTGAAATGAACTC 13q14.3 2
hsa-miR-5694-5p CAGATCATGGGACTGTCTCAG 14q23.3 2
hsa-miR-5695-3p ACTCCAAGAAGAATCTAGACAG 19p13.13 2
hsa-miR-5696-5p CTCATTTAAGTAGTCTGATGCC 2q11.2 2
hsa-miR-5697-5p TCAAGTAGTTTCATGATAAAGG 1p36.22 2
hsa-miR-5698-5p TGGGGGAGTGCAGTGATTGTGG 1q21.3 2
hsa-miR-5699-3p TCCTGTCTTTCCTTGTTGGAGC 10p15.3 2
hsa-miR-5700-5p TAATGCATTAAATTATTGAAGG 12q22 2
hsa-miR-5701-5p TTATTGTCACGTTCTGATT 15q11.2 2
hsa-miR-5702-3p TGAGTCAGCAACATATCCCATG 2q36.3 2
hsa-miR-5703-3p AGGAGAAGTCGGGAAGGT 2q36.3 2
hsa-miR-5692b-5p AATAATATCACAGTAGGTGT 21q22.3 2
hsa-miR-5704-5p TTAGGCCATCATCCCATTATGC 3q22.1 2
hsa-miR-5705-3p TGTTTCGGGGCTCATGGCCTGTG 4q22.1 2
hsa-miR-5706-5p TTCTGGATAACATGCTGAAGCT 5q23.1 2
hsa-miR-5707-5p ACGTTTGAATGCTGTACAAGGC 7q36.3 2
hsa-miR-5708-5p ATGAGCGACTGTGCCTGACC 8q21.13 2
doi:10.1371/journal.pone.0024950.t004
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cells (Fig. 1B). Although this result has borderline significance
(p=0.08), it indicates that increased expression of miR-486
enhances tissue invasiveness.
Discussion
MicroRNAs have been implicated in the regulation of gene
expression at the post-transcriptional level in almost every
biological event, and there is an increasing body of evidence that
altered expressions of specific miRNAs are involved in the
development and progression of cancers [4,5]. Using next
generation sequencing for small RNA identification, the present
study was aimed at identifying differentially expressed known and
novel miRNAs in metastatic versus non-metastatic prostate cancer
xenografts that could play a role in the progression of prostate
cancer to the metastatic form. The transplantable cancer lines that
were used appear to be highly suitable for the purpose since they
had been derived from one patient’s cancer and thus possessed a
common genetic background. Furthermore, they had been
developed via subrenal capsule grafting of cancer tissue into
NOD/SCID mice, a methodology that tends to preserve
important properties of the original cancers (e.g., tumor
heterogeneity, genetic profiles) [9–11,50]. As well, the mainte-
nance of the tumor lines in the same type of graft site (under the
kidney capsule) ensured that their growth was not markedly
influenced by micro-environmental differences that can have an
important impact on cancer development [51]. Similarly, the same
type of graft site would minimize differences in miRNA production
by host cells present in the xenografts. Although it has been shown
Table 5. miRNAs down-regulated in the metastatic library
1.
references
prostate cancer metastasis in
miRNA metastatic non-metastatic fold change prostate cancer
other types of
cancer
miR-7-1* 2.76 24.54 28.88
miR-15b 489.84 2660.69 25.43 [28]
#
miR-16 999.03 17741.34 217.76 [23–25], [38]
# [25]
miR-24 1046.96 8903.54 28.50 [26–28], [76]
# [61]
miR-24-2*{ 5.07 22.50 24.44
miR-26b 1964.89 8991.18 24.58 [28]
#
miR-28-5p 184.78 1264.17 26.84
miR-29a 446.06 13028.23 229.21 [26,28,29]
miR-29c 299.99 1643.68 25.48
miR-33b 22.12 62.81 22.84
miR-34a 76.03 194.87 22.56 [77], [26]
# [33] [78]
miR-95 57.60 1128.90 219.60 [26]
#
miR-101*{ 4.61 105.76 222.95
miR-106b 906.41 6545.23 27.22 [30]
#
miR-126* 1099.03 3798.06 23.46 [28]
# [34]
miR-145 103.68 297.71 22.87 [23,24,27,29,30] [35] [61]
miR-146b-5p 1335.88 2765.57 22.07 [26]
# [79], [61]
#
miR-185 84.79 448.76 25.29 [60]
miR-186 1666.28 5838.21 23.50 [61]
#
miR-188-5p 0.92 9.64 210.46
miR-191 1822.50 12911.66 27.08 [26]
#
miR-193a-3p 35.94 196.91 25.48
miR-195 116.58 560.65 24.81 [23], [26]
#
miR-196a 33.64 70.99 22.11 [26]
#
miR-200b* 146.54 499.30 23.41
miR-200c* 12.44 54.34 24.37
miR-203 147.92 434.73 22.94 [26]
# [61]
miR-203{ 224.41 334.81 21.49 [26]
#
miR-205 0.00 31.26 N/A [24,31,32] [36]
{most abundant miRNA started one base upstream from the mature form of miRBase.
{most abundant miRNA started one base downstream from the mature form of miRBase.
1Differential expressions all had a .2-fold change and a p,0.001 and are considered statistically significant.
#Results from the literature that do not match the down- or up-regulation found in the present study.
doi:10.1371/journal.pone.0024950.t005
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study focused primarily on differences in miRNAs between
matched samples and these differences are therefore likely to be
real. Taken together, the data obtained in this study should be
useful for the delineation of miRNAs with oncogenic properties
that are involved in the development of prostate cancer metastasis.
The highest reads in the two RNA libraries were observed for
miR-148a. The expression of this miRNA is androgen-inducible in
LNCaP cells [53]. This suggests that the relatively high expression
of miR-148a found in the two libraries is a result of the
testosterone supplementation of the animals.
Of the 104 miRNAs that were found to be down- or up-
regulated in the metastatic prostate cancer xenografts, relative to
their non-metastatic counterparts, 39 had previously been
reported to be involved in prostate cancer (Table 5,6,7). These
reports were mostly based on comparisons of miRNA expressions
in prostate cancer tissues versus normal prostate tissues without
defining the metastatic ability of the malignant samples. It is of
interest that 21 of the 39 miRNAs showed down- or up-regulations
in the metastatic xenografts which matched those reported for the
prostate cancer tissues (relative to benign tissues), suggesting that
these prostate cancer tissues may have had metastatic ability. Of
the miRNAs found to be down-regulated in the metastatic
xenografts, miR-16, showing a .17-fold decrease in expression,
has been reported to be down-regulated in prostate cancer [23,24]
and to have a metastasis-suppressing function. Moreover,
metastatic prostate tumor growth in vivo could be inhibited by
systemic delivery of synthetic miRNA-16 [25]. The reduced
expression of miR-34a in the metastatic xenograft line is consistent
with its reported inhibition of prostate cancer metastasis [33]. The
lower expression of miR-126* is in agreement with reports that
this miRNA is down-regulated in prostate cancer metastasis [34]
and that ectopic expression of miR-126* inhibited the migration
and invasiveness of prostate cancer cells [34]. The latter being an
example of a miRNA* playing a role as a tumor suppressor.
Interestingly, miR-126, a miRNA reported as down-regulated in
prostate cancer relative to normal prostate tissue [54], was up-
regulated in the metastatic xenograft line. In this context it is of
interest that whereas in LNCaP cells, the antagomir of miR-126
did not affect cell migration, the antagomir of miR-126* induced
Table 6. miRNAs down-regulated in the metastatic library
1(Continued from Table 5).
references
prostate cancer metastasis in
miRNA metastatic non-metastatic fold change prostate cancer other types of cancer
miR-324-5p 27.19 61.94 22.28
miR-331-3p 2.76 14.32 25.18 [80]
miR-335 22.58 54.63 22.42 [62]
miR-339-5p 35.94 189.03 25.26
miR-342-3p 61.75 247.46 24.01
miR-361-5p 103.68 259.73 22.51
miR-363 1298.10 8476.40 26.53
miR-424 22.12 76.25 23.45 [28]
miR-425 1869.04 10985.75 25.88
miR-454 10.60 32.72 23.09
miR-497 164.05 373.67 22.28 [23]
miR-503 0.00 7.30 N/A [23]
#
miR-542-5p 0.92 12.27 213.31
miR-556-5p 1.84 13.15 27.13 [26]
#
miR-582-5p 49.77 203.93 24.10
miR-590-5p 12.44 213.86 217.19
miR-627 2.30 93.20 240.45
miR-651 11.06 54.63 24.94
miR-652 12.90 33.89 22.63
miR-660 51.15 110.14 22.15
miR-664 8.76 30.97 23.54
miR-708 0.00 42.36 N/A
miR-1180 3.69 15.48 24.20
miR-1269 11.06 42.66 23.86
miR-1287 1.84 12.85 26.97
miR-2115* 0.00 7.89 N/A
miR-3065-5p 14.75 117.74 27.98
1Differential expressions all had a .2-fold change and a p,0.001 and are considered statistically significant.
#Results from the literature that do not match the down- or up-regulation found in the present study.
doi:10.1371/journal.pone.0024950.t006
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1.
references
prostate cancer metastasis in
miRNA metastatic non-metastatic fold change prostate cancer other types of cancer
let-7d 671.86 322.84 2.08 [26]
let-7g 8690.38 3448.64 2.52 [23]
#
let-7g* 42.39 3.21 13.19
let-7i 851.11 400.55 2.12 [26] [61]
miR-7 72.35 22.50 3.22
miR-9 20121.64 1386.00 14.52 [65],[61]
#
miR-9*{ 352.98 35.64 9.90
miR-17 12228.92 5600.39 2.18
miR-18a 1023.45 142.57 7.18
miR-18b 90.78 26.59 3.41
miR-20b* 89.40 7.60 11.77
miR-27a 1568.59 721.34 2.17 [26], [28]
#
miR-27b 1406.39 425.38 3.31 [28]
#
miR-30a 30144.22 10956.83 2.75 [61]
#
miR-30a* 1300.40 532.90 2.44
miR-31 80.64 3.80 21.23 [30], [24]
# [67,81]
miR-34c-5p 2190.22 51.13 42.84
miR-99a 1017.92 330.43 3.08 [23]
#
miR-106a 2790.65 845.51 3.30 [26],[28] [38]
#
miR-125b 1699.46 287.19 5.92 [38–40], [23,24,27,29]
# [61]
miR-125b-2* 15.67 1.46 10.73 [57]
miR-126 26005.24 1799.70 14.45 [54]
#
miR-128 81.10 15.48 5.24 [26]
#
miR-136 40.55 7.89 5.14
miR-138 38.25 1.46 26.18
miR-140-5p 2458.87 723.97 3.40
miR-142-5p 104.60 26.00 4.02 [61]
miR-144 915.16 134.98 6.78
miR-144* 5429.24 418.37 12.98
miR-148b*{ 258.97 111.31 2.33
miR-151-3p 4377.22 1866.89 2.34 [66]
miR-152 2662.55 582.56 4.57 [28]
#
miR-181a-2* 19.81 0.88 22.61
miR-200a 7217.64 1066.09 6.77 [58]
#
miR-210 16686.78 347.38 48.04 [23]
miR-218 140.55 70.12 2.00 [25],[26]
#
miR-223* 16.13 0.29 55.20
miR-301a 60.83 21.62 2.81 [37]
miR-340* 46.08 16.36 2.82
miR-374a 1638.17 674.30 2.43
miR-379 104.14 35.94 2.90
miR-449a 18.43 1.17 15.77 [59]
#
miR-450a 191.24 24.83 7.70 [61]
miR-451 4504.40 2197.62 2.05
miR-486-3p 9.22 0.88 10.52
miR-486-5p 430.86 54.93 7.84
miR-542-3p 100.00 26.88 3.72
miR-744* 17.05 3.80 4.49
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miR-126* affects cell migration more than miR-126. This raises
the possibility that alternative strand selection as a mechanism for
changing the expression of either arm is involved in the
development of cancer or cancer metastasis.
The down-regulation of miR-145 in the metastatic xenograft
line is in agreement with many reports identifying it as down-
regulated in prostate tumors [23,24,27,29,30]. As well, a role for
miR-145 in prostate cancer metastasis is suggested by its down-
regulation observed in clinical samples of metastatic prostate
cancer relative to localized high grade prostate cancer [35];
furthermore, miR-145 is considered a putative tumor suppressor
in colon cancer cells [55] and can reduce breast cancer cell
motility [56]. The expression of miR-205 was also reported to be
down-regulated in prostate cancer cells, and ectopically expressed
miR-205 showed a tumor-suppressive effect, including reduction
of cell migration and tissue invasion [36].
Of the miRNAs found to be up-regulated in the metastatic
xenografts, miR-125b has been reported to be up-regulated in
prostate cancer and shown to be oncogenic [24,29,40]; other
studies, however, have reported miR-125b to be down-regulated
in prostate cancer [23,24,27–29]. miR-125b-2, a component of the
miR-125b cluster, has been identified as part of an androgen
receptor-mediated transcriptional network [57]. In a number of
single studies, miRNAs such as let-7d [26], let-7i [26] and miR-
210 [23] were also found to be up-regulated in prostate cancer, in
contrast to let-7g [23], miR-27b [28], miR-99a [23], miR-126
[54], miR-128 [26], miR-152 [28], miR-200a [58] and miR-449a
[59] which were down-regulated in prostate cancer samples. Both
up- and down-regulation in prostate cancer was reported for a
number of miRNAs. The reason for these discrepancies is not
clear. Our finding indicating that upregulation of miR-486 is
coupled to increased tissue invasiveness, as found with 22Rv1
human prostate cancer cells (Fig. 1b), supports the biological
significance of the present study.
It is apparent from the above discussion that a number of the
differentially expressed miRNAs identified in this study probably
have a significant role in prostate cancer metastasis. Thus some of
the miRNAs have already been linked to this phenomenon, in
particular down-regulated miRNAs such as miR-16, miR-34a,
miR-126*, miR-145 and miR-205, supporting the validity of our
analytical approach. However, the prostate cancer xenografts did
not show significant differential expression for miRNAs such as
miR-221, whose down-regulation in a study using prostate cancer
samples from a large number of patients was reported to be a
hallmark in human prostate cancer metastasis [37]. This
deficiency likely stems from the tumor heterogeneity of prostate
cancers and illustrates the need for using a larger number of
matched metastatic and non-metastatic xenografts and also
clinical samples.
The present study has also identified differentially expressed
miRNAs that have not previously been linked to prostate cancer,
references
prostate cancer metastasis in
miRNA metastatic non-metastatic fold change prostate cancer other types of cancer
miR-1246{ 95.39 22.50 4.24
{most abundant miRNA started one base upstream from the mature form of miRBase.
{most abundant miRNA started one base downstream from the mature form of miRBase.
1Differential expressions all had a .2-fold change and a p,0.001 and are considered statistically significant.
#Results from the literature that do not match the down- or up-regulation found in the present study.
doi:10.1371/journal.pone.0024950.t007
Table 7. Cont.
Figure 1. Effects of overexpression of miR-486 on proliferation
and tissue invasiveness of 22Rv1 human prostate cancer cells.
A) As indicated by MTT assay, there was no significant difference
between the growth of miR-486-transfected cells and control cells over
a 72-hr period. B) Tissue invasiveness, as measured by Matrigel invasion,
of miR-486 transfected cells and control cells. Data are expressed as
percent invasiveness 6 S.D. and show increased invasiveness of miR-
486-transfected cells (85% ; p=0.08).
doi:10.1371/journal.pone.0024950.g001
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miRNAs down-regulated in the metastatic xenografts, miR-185
has been shown to suppress growth and progression of certain
human cancers (e.g., breast, ovary) by targeting the Six1 oncogene
which regulates c-myc expression [60]. The miR146b-5p [61] and
miR-335 [62] miRNAs have been shown to be metastasis
suppressors in breast and colon cancers, facilitating the metastatic
phenotype at reduced levels [63]. Of the up-regulated miRNAs in
the metastatic line, miR-9 has been reported to target E-cadherin
[64] and CDH1, the E-cadherin-encoding messenger RNA [65];
overexpression of miR-9 in non-metastatic breast tumor cells
enables such cells to form pulmonary micrometastases in mice
[65]. The miR-30a, miR-142-5p and miR-450a have roles in
metastatic breast and colon cancer [61] and the miR-151-3p can
enhance hepatocellular carcinoma cell mobility [66]. The
upregulation of miR-31 is consistent with its ability to induce
migration and tissue invasion of colon cancer cells via targeting of
T-cell lymphoma invasion and metastasis 1 (TIAM1) [67]. It
appears likely that these miRNAs also have a critical role in the
development of prostate cancer metastasis on the basis of their role
in the metastasis of other cancers, but further validation is needed.
The identification of novel putative miRNAs (Table 4) is of
major interest for follow-up studies. In advanced prostate cancer,
DNA copy number gain is commonly observed in the chromo-
some 8q arm [68], and the LTL-313 xenograft lines that were used
in the present study also show an 8q arm copy number gain (data
not shown). The finding that five of the 46 novel miRNAs were
located on chromosome 8q, including the most abundantly
expressed candidates (Table 4), suggests that there is a correlation
between tissue-specific expression of an miRNA and its DNA copy
number.
As found in the present study, some of the miRNA*s (identified
by miRBase) are more highly expressed than their corresponding
miRNAs (Table 2). This is likely a result of cancer-induced
changes in miRNA processing and stability, including strand
selection [69]. The latter is thought to normally involve an RNA-
Induced Silencing Complex (RISC), a multiprotein complex that
can incorporate one strand of an miRNA for subsequent silencing
of the complementary mRNA [70]. Switching of a strand should
lead to activation/inhibition of a different set of target genes and
may underlie oncogenic properties of miRNA*s. There are several
reports of miRNA* contributions in cancer progression [34,71,72].
The occurrence of miRNA isoforms (isomiRs) in the present
study has also been observed in other studies using miRNA deep
sequencing [16]. The variability in isomiR expression during
Drosophila melanogaster development, generally thought to result
from inexact Dicer processing and RNA editing, may not be
arbitrary and in fact be regulated and biologically meaningful [73].
At present, the contribution of isomiRs in target recognition is not
clear. However, it appears likely that the seed sequence of mature
miRNA, i.e. the first 2–8 nucleotides at the 59 end, is a key of the
miRNA’s target recognition and a variation of the 59 end could
readily alter the group of target genes of the miRNA. Likewise, the
role of isomiRs in cancer has to be elucidated. Lee et al. [74] have
constructed a database cataloguing an entire repertoire of miRNA
sequences that can be useful for showing isomiR expression
pattern differences in various cell types and conditions. The role of
the differentially expressed miRNAs, including miRNA*, isomiR
and novel miRNA (candidates), in the development of metastatic
prostate cancer remains to be shown. Use of patient-derived
prostate cancer xenograft models in conjunction with clinical
sample analysis and in vitro models may bring unique perspectives
to translational research.
It is of interest that many of the genes associated with the
differentially expressed mRNAs in the xenografts were found to be
identical to predicted target genes of differentially expressed
miRNAs, and that they were related to cancer and metastasis, e.g.,
FSCN1 [42], CCL2 [46], ADAMTS1 [45], FGFR1 [44], CTGF [48]
and SERPINB5 [49]. However, while an miRNA potentially has
hundreds of target genes, relatively few targets have been
experimentally validated and few miRNA loss-of-function pheno-
types have been assigned [75]. More research is required into the
effect of specifically inhibiting/enhancing the function of miRNAs
on the activity of their putative target genes, gene translation and
the various stages of cancer development.
In summary, we have utilized next generation sequencing to
identify differentially expressed known and novel miRNAs in a
pair of metastatic and non-metastatic prostate cancer xenografts
derived from one patient’s primary cancer. The use of xenografts
generated by subrenal capsule grafting of cancer tissue, a
technique that tends to preserve properties of the original cancers,
coupled to the finding that a substantial number of the
differentially expressed genes have previously been linked to
metastasis of prostate cancer or other types of cancer, makes it
likely that the identified miRNAs include potential biomarkers
and/or therapeutic targets for prostate cancer metastasis.
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